BUZZ-Travere Therapeutics 预测第四季度销售额低于预期，业绩下滑

路透中文

Jan 13

BUZZ-Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 预测第四季度销售额低于预期，业绩下滑

1月13日 - ** 药物开发商 Travere Therapeutics TVTX.O 股价下跌 25.9% 至 25.58 美元

** 该公司周一晚些时候表示，预计第四季度美国总销售额约为1.27亿美元，低于华尔街预计的1.422亿美元--数据由LSEG编译

** 公司预计 2025 年美国总销售额约为 4.1 亿美元，低于华尔街预计的 5.0296 亿美元。

** 公司将于 2026 年第一季度重新启动实验性疗法 pegtibatinase 在罕见代谢性疾病患者中的后期研究

** TVTX称已回应美国食品及药物管理局的要求，提供更多有关Filspari对局灶节段性肾小球硬化症患者疗效的数据，该局正在审查这些呈件

** 截至上次收盘，该公司股价在过去 12 个月中上涨了 83.4%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603635310"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603635310\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603635310?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-13 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603635310","market":"hk","top_or_hot":-1,"title":"BUZZ-Travere Therapeutics 预测第四季度销售额低于预期，业绩下滑","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 预测第四季度销售额低于预期，业绩下滑</title></head><body><p><span>1月13日</span><span> - </span>** 药物开发商 Travere Therapeutics <span>TVTX.O</span> 股价下跌 25.9% 至 25.58 美元 </p><p>** 该公司周一晚些时候表示，预计第四季度美国总销售额约为1.27亿美元，低于华尔街预计的1.422亿美元--数据由LSEG编译 </p><p>** 公司预计 2025 年美国总销售额约为 4.1 亿美元，低于华尔街预计的 5.0296 亿美元。 </p><p>** 公司将于 2026 年第一季度重新启动实验性疗法 pegtibatinase 在罕见代谢性疾病患者中的后期研究</p><p>** TVTX称已回应<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局的要求，提供更多有关Filspari对局灶节段性肾小球硬化症患者疗效的数据，该局正在审查这些呈件</p><p>** 截至上次收盘，该公司股价在过去 12 个月中上涨了 83.4%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Travere Therapeutics 预测第四季度销售额低于预期，业绩下滑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Travere Therapeutics 预测第四季度销售额低于预期，业绩下滑\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-13 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 预测第四季度销售额低于预期，业绩下滑</title></head><body><p><span>1月13日</span><span> - </span>** 药物开发商 Travere Therapeutics <span>TVTX.O</span> 股价下跌 25.9% 至 25.58 美元 </p><p>** 该公司周一晚些时候表示，预计第四季度美国总销售额约为1.27亿美元，低于华尔街预计的1.422亿美元--数据由LSEG编译 </p><p>** 公司预计 2025 年美国总销售额约为 4.1 亿美元，低于华尔街预计的 5.0296 亿美元。 </p><p>** 公司将于 2026 年第一季度重新启动实验性疗法 pegtibatinase 在罕见代谢性疾病患者中的后期研究</p><p>** TVTX称已回应<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局的要求，提供更多有关Filspari对局灶节段性肾小球硬化症患者疗效的数据，该局正在审查这些呈件</p><p>** 截至上次收盘，该公司股价在过去 12 个月中上涨了 83.4%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL4T3YE1KB:1","article_id":"2603635310","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603635310","pubTimestamp":1768318019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Travere Therapeutics 预测第四季度销售额低于预期，业绩下滑1月13日 - ** 药物开发商 Travere Therapeutics TVTX.O 股价下跌 25.9% 至 25.58 美元 ** 该公司周一晚些时候表示，预计第四季度美国总销售额约为1.27亿美元，低于华尔街预计的1.422亿美元--数据由LSEG编译 ** 公司预计 2025 年美国总销售额约为 4.1 亿美元，低于华尔街预计的 5.0296 亿美元。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TVTX":"Travere Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Travere Therapeutics forecasts lower-than-expected Q4 sales, results slip","themeId":"c1e92389ea3348eefdedc3b957de184b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"BUZZ-Travere Therapeutics 预测第四季度销售额低于预期，业绩下滑1月13日 - ** 药物开发商 Travere Therapeutics TVTX.O 股价下跌 25.9% 至 25.58 美元 ** 该公司周一晚些时候表示，预计第四季度美国总销售额约为1.27亿美元，低于华尔街预计的1.422亿美元--数据由LSEG编译 ** 公司预计 2025 年美国总销售额约为 4.1 亿美元，低于华尔街预计的 5.0296 亿美元。 ** 公司将于 2026 年第一季度重新启动实验性疗法 pegtibatinase 在罕见代谢性疾病患者中的后期研究** TVTX称已回应美国食品及药物管理局的要求，提供更多有关Filspari对局灶节段性肾小球硬化症患者疗效的数据，该局正在审查这些呈件** 截至上次收盘，该公司股价在过去 12 个月中上涨了 83.4%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}